Latest TroVax Stories
Quality of life measures seem to be most useful for clinical decision-making in trials where quality of life is the primary outcome, according to a new study.
BRIDGEWATER, N.J., Jan.
SAN FRANCISCO and ILLKIRCH, France, Dec.
WORCESTER, Mass., Nov. 10, 2010 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT) announced today that its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc.
Even though the cancer-treatment agent cetuximab is not considered effective treatment for KRAS (a gene)-mutated metastatic colorectal tumors, new research indicates that patients with colorectal cancer not responding to chemotherapy and a certain variation of this gene who were treated with cetuximab had longer overall and progression-free survival than patients with other KRAS-mutations.
CINCINNATI, Oct. 12 /PRNewswire-USNewswire/ -- A clinical trial testing a genetically reprogrammed herpes simplex virus as treatment for deadly forms of childhood cancer has received a U.S.
TUEBINGEN, Germany, September 21, 2010 /PRNewswire/ -- - New Investment Allows immatics to Perform Pivotal Study With its Lead Vaccine IMA901 in Patients With Renal Cell Carcinoma (RCC) - Study to Start in 2010 - IMA901 Phase II Trial has Shown the Potential to Confer an Overall Survival Benefit - Financing Supported by Both New and Existing Investors immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active...
Lung cancer researchers have identified a genetic signature that can help doctors determine which patients with early-stage non-small cell lung cancer are at high risk for developing disease recurrence and therefore may benefit from chemotherapy after surgery ("adjuvant chemotherapy").
BRUSSELS, August 19, 2010 /PRNewswire/ -- Using the innovative technique of radioembolisation to treat patients with inoperable colorectal cancer liver metastases who have failed all standard-of-care chemotherapy options can more than double the time until their disease progresses, according to the final results of a Phase III randomised controlled trial published in the prestigious Journal of Clinical Oncology.(1) The prospective, randomised trial compared a protracted infusion of...
COLUMBIA, Md., Aug.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.